Publications by authors named "Joseph Tuscano"

Claim this Profile
A
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.
Joseph M Tuscano, Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis, Joseph Tuscano

J Natl Compr Canc Netw· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.
Sarah C Rutherford, Hongli Li, Alex F Herrera, Michael LeBlanc, Sairah Ahmed, Joseph M Tuscano

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Light chain crystalline podocytopathy caused by electron-lucent crystals - a diagnostic challenge: a case report.
Rajib K Gupta, Maria E Pagtalunan, Ann M Wexler, Joseph M Tuscano

Ultrastruct Pathol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphoma Therapy Response Assessment with Low-Dose [F]FDG Total-Body PET/CT.
Clemens Mingels, Kevin J Chung, Hande Nalbant, Yasser G Abdelhafez, Naseem S Esteghamat, Joseph M Tuscano

J Nucl Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503).
Brian A Jonas, Samantha C Fisch, Peter T Curtin, Gary J Schiller, Deepa Jeyakumar, Joseph M Tuscano

Leuk Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis.
Aaron S Rosenberg, Emanual Maverakis, Caitlin Costello, Elizabeth A Brem, Matthew Joseph Wieduwilt, Joseph Tuscano

Blood Neoplasia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma.
Tamer Othman, Gabriel Marquez-Arreguin, Naseem Esteghamat, Joseph Tuscano

Leuk Lymphoma· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.
Tamer Othman, Paul Frankel, Pamela Allen, Leslie L Popplewell, Geoffrey Shouse, Joseph Tuscano

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities.
Clemens Mingels, Hande Nalbant, Hasan Sari, Felipe Godinez, Fatma Sen, Joseph M Tuscano

PET Clin· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Alex F Herrera, Michael LeBlanc, Sharon M Castellino, Hongli Li, Sarah C Rutherford, Joseph M Tuscano

N Engl J Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma.
Naseem Esteghamat, Aaron Tsumura, Gabriel Marquez-Arreguin, Joseph Tuscano

Front Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In Vivo.
Joshua F Meckler, Daniel J Levis, Yanguo Kong, Robert T O'Donnell, Daniel P Vang, Joseph M Tuscano

Int J Mol Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
Michael Durando, Ajay K Gopal, Joseph Tuscano, Daniel Persky

Oncologist· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis, Joseph Tuscano

J Natl Compr Canc Netw· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Tamer Othman, Michelle A Quan, Shiliang Zhang, Daria Gaut, Patricia A Young, Joseph Tuscano

Clin Lymphoma Myeloma Leuk· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma.
Tamer Othman, Robert Lowsky, Carol Richman, Rasmus Hoeg, Mehrdad Abedi, Joseph Tuscano

Bone Marrow Transplant· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Checkpoint inhibition in hematologic malignancies.
Aaron Tsumura, Daniel Levis, Joseph M Tuscano

Front Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
Joshua F Meckler, Daniel J Levis, Daniel P Vang, Joseph M Tuscano

Cancer Immunol Immunother· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo.
Daniel J Levis, Joshua F Meckler, Robert T O'Donnell, Joseph M Tuscano

Curr Issues Mol Biol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML.
Brian A Jonas, Laura A Potter, Maria Galkin, Joseph M Tuscano

Leuk Res Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.
Julio C Chavez, Francine M Foss, Basem M William, Jonathan E Brammer, Sonali M Smith, Joseph M Tuscano

Clin Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy.
Samantha C Fisch, Joseph M Tuscano, Lihong Qi, Brian A Jonas

Leuk Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Tamer Othman, Juan Penaloza, Shiliang Zhang, Claire E Daniel, Daria Gaut, Joseph Tuscano

Clin Lymphoma Myeloma Leuk· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Tamer Othman, Benjamin N Moskoff, Gwendolyn Ho, Matthew E Tenold, Tali Azenkot, Joseph M Tuscano

Leuk Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis